CoChat

Exenatide efficacy and safety: a systematic review

Norris, S. L., Lee, N., Thakurta, S., Chan, B. K. S. · 2009 · Diabetic Medicine
Cited by 88

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Objective To examine the efficacy, effectiveness and side effects of exenatide when compared with oral glucose‐lowering agents or insulin therapy. Research design and methods Relevant citations were identified from searches of multiple bibliographic databases supplemented with searches of the US Food and Drug Administration website and other sources. A qualitative synthesis was performed, with a random effects meta‐analysis when appropriate. Results We identified 17 studies. In placebo‐controlled trials of subjects with poorly controlled diabetes (with both groups receiving various oral glucose‐lowering agents), exenatide 10 μg twice daily improved glycated haemoglobin (HbA 1c) by approximately 1.0% over 30 weeks [pooled estimate −0.97%, 95% confidence interval (CI), −1.16 to −0.79%, P < 0.0001] and exenatide treatment over 16–30 weeks was associated with weight loss of 1.0–2.5 kg. Exenatide appeared to confer a similar benefit to various insulin regimes for glycaemic control at follow‐up between 16 and 52 weeks (pooled estimate HbA 1c−0.04%, 95% CI, −0.14 to 0.06%, P = 0.41), but was advantageous over insulin with respect to weight loss (3–6 kg loss at up to 52 weeks of follow‐up). Nausea was the most common adverse event in placebo‐ and active‐controlled trials. Rates of hypoglycaemia were similar in exenatide and insulin groups, but were higher with exenatide 10 μg twice daily compared with placebo and hypoglycaemia was most frequent when a sulphonylurea was administered. Conclusions In subjects with poorly controlled diabetes, exenatide was associated with a reduction in HbA 1c that was similar to introducing another oral agent or insulin. Weight loss may be an advantage with exenatide. Long‐term studies in diverse and unselected populations are needed to clarify the benefit vs. harm profile of this drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2009.02790.x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 88

Metadata

Authors
Norris, S. L., Lee, N., Thakurta, S., & Chan, B. K. S.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2009-08-26
Volume
26
Issue
9
Pages
837-846
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1984430136
Cited by
88
References
13
FWCI
1.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide efficacy and safety: a systematic review. https://app.cochat.ai/papers/10.1111/j.1464-5491.2009.02790.x
The paper
Norris, S. L., Lee, N., Thakurta, S., & Chan, B. K. S. (2009). Exenatide efficacy and safety: a systematic review. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2009.02790.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.